Scott Moomaw serves as Chief Commercial Officer at Liquidia Corporation, a biopharmaceutical company developing innovative products for pulmonary and orphan diseases. With more than 25 years of experience in the pharmaceutical industry, Scott specializes in commercial strategy, sales leadership, and market access for respiratory therapies and rare diseases. His career has been marked by successfully launching and scaling therapies that address unmet needs in pulmonary arterial hypertension (PAH) and related conditions. Prior to joining Liquidia in 2022, Scott held senior roles at United Therapeutics Corporation, including Senior Vice President of Commercial Operations for North America, where he led the commercialization of key products such as Tyvaso and Remodulin. These efforts resulted in substantial revenue growth, expanded market share, and improved patient access to life-saving treatments. Earlier positions at Inspire Medical Systems, Ikaria, and Theravance Biopharma further solidified his expertise in inhaled therapies, team building, and driving commercial excellence across complex therapeutic areas. At Liquidia, Scott directs all commercial functions, including the strategic launch and lifecycle management of YUTREPIA (treprostinil) inhalation powder, the company's first FDA-approved product for PAH and PH-ILD. His leadership is pivotal in navigating market dynamics, payer negotiations, and field execution to deliver transformative therapies, positioning Liquidia for sustained growth and impact on patient outcomes.